The data is still preliminary, but the results might help Qneza eventually become the first drug for sleep apnea. Right now, the condition can only be treated with devices.
Joined by Orexigen Therapeutics Inc and Arena Pharmaceuticals Inc., Vivus is one of three companies hoping to get regulatory approval of new oral obesity treatments. The company recently submitted a new drug application to the Food and Drug Administration for that use.
The findings may further bolster Vivus's resume in its search for a Big Pharma partner for the anti-obesity drug.
Vivus shares were up 5.5% to $9.69.
About EQUITIES:
Since 1951, EQUITIES Magazine has been a leading media company providing business editorial content designed to serve the needs of business leaders, professionals, institutional investors and retail investors. We are focused on business and the business of making money, not on lifestyle subjects. We publish original reporting in print and on our website, as well as select content at www.nasdaq.com. For 28 years we have hosted our own branded investor conferences that connect public company CEO’s with our loyal readers in the investment community.
Sign up for a free one-year subscription to EQUITIES Magazine
